Stemmatters is a regenerative medicine company focused on R&D and manufacturing of cell based products.
The company is developing new biomaterials and tissue engineering products for cartilage repair and regeneration, which demonstrate benefit as compared to current standard of care. In addition to its R&D infrastructure, headquarters comprise clean rooms for processing of tissues and cells and contract manufacturing of cell based products. Stemmatters has a QMS compliant with GLP, GMP and ISO 9001:2008.
|
|
|
PRODUCTS & SERVICES
Stemmatters develops innovative regenerative medicine products that progress standard of care and improve quality of life. Our products under development target:
/ Osteoarthritis: New glycosaminoglycan analogue formulation to be administered by intra-articular injection, exhibiting prolonged degradation time and enhanced bioactive profile, aimed at promoting chondroprotection in diseased joints.
/ Cartilage lesions: Novel tissue engineering product aimed at addressing focal cartilage lesions, which enables single step treatment of patients by a minimally invasive procedure, and speeds up recovery time, while reducing treatment cost in an outpatient setting.
Stemmatters provides contract research and development in medical devices and advanced therapy medicinal products, by encompassing experimental development, in vitro performance assessment and in vivo testing. Stemmatters assures manufacturing of cell based products in compliance with current regulations and cGMP guidelines.
|
|
TARGET MARKETS / CLIENTS
Markets:
Regenerative medicine
Tissue Engineering
3D cell culture systems
Clients:
Pharmaceutical and biotechnology companies or institutions engaged in experimental, pre-clinical and clinical research in the area of tissue engineering and regenerative medicine.
Pharmaceutical and biotechnology companies engaged with the development and application of 3D cell culture systems.
Companies interested in developing regenerative medicine products targeting musculoskeletal diseases.
|
